Harrow (HROW) Cash from Investing Activities (2012 - 2026)
Harrow's (HROW) quarterly Cash from Investing Activities came in at -$18.2 million in Q1 2026, down 8486.32% year-on-year from $217055.9 in Q1 2025, and down 284.84% quarter-over-quarter from -$4.7 million in Q4 2025.
Harrow (HROW) Cash from Investing Activities (2012 - 2026) Analysis & Trends
Harrow's Cash from Investing Activities history runs 15 years deep, the most recent figure standing at -$18.2 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 8486.32% year-over-year to -$18.2 million in Q1 2026; TTM through Mar 2026 was -$23.5 million, a 29.5% increase from a year earlier, with the FY2025 full-year figure at -$5.5 million, up 83.54% from the prior year.
- Cash from Investing Activities eased to -$18.2 million in Q1 2026 per HROW's latest filing, from -$4.7 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $5.1 million in Q2 2024 and bottomed at -$131.0 million in Q1 2023.
- The 5-year median for Cash from Investing Activities is -$410000.0 (2022), against an average of -$12.4 million.
- Across the five-year window, Cash from Investing Activities sank 31843.9% in 2023 and soared 508.57% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$5000.0 in 2022, then tumbled by 3960.0% to -$203000.0 in 2023, then slumped by 18402.46% to -$37.6 million in 2024, then jumped by 87.41% to -$4.7 million in 2025, then sank by 284.84% to -$18.2 million in 2026.
- Per Business Quant, the three latest HROW Cash from Investing Activities figures stand at -$18.2 million (Q1 2026), -$4.7 million (Q4 2025), and -$225000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 229.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -87.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -369.95 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 743.70 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 277.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -506.20 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -60.00 Mn |
| 10 | Harrow | 1.41 Bn | 1.32 Bn | 27.05 Mn | -18.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.20 Mn |
| Mar 31, 2026 | -18.20 Mn |
| Dec 31, 2025 | -4.73 Mn |
| Dec 31, 2025 | -4.73 Mn |
| Sep 30, 2025 | -225,000.00 |
| Sep 30, 2025 | -225,000.00 |
| Jun 30, 2025 | -293,000.00 |
| Jun 30, 2025 | -293,000.00 |
| Mar 31, 2025 | -212,000.00 |
| Mar 31, 2025 | -212,000.00 |
| Dec 31, 2024 | -37.56 Mn |
| Dec 31, 2024 | -37.56 Mn |
| Sep 30, 2024 | -597,000.00 |
| Sep 30, 2024 | -597,000.00 |
| Jun 30, 2024 | 5.10 Mn |
| Jun 30, 2024 | 5.10 Mn |
| Mar 31, 2024 | -110,000.00 |
| Mar 31, 2024 | -110,000.00 |
| Dec 31, 2023 | -203,000.00 |
| Dec 31, 2023 | -203,000.00 |